BASINGSTOKE, England, November 23 /PRNewswire-FirstCall/ -- The Company
announces that it was notified on 22 November 2005 under Sections 198 to 203
of the Companies Act that, at close of business on 17 November 2005, The
Goldman Sachs Group, Inc., was interested in 27,000,376 ordinary shares of
GBP0.05p each in the capital of the Company. This holding represents 5.452
per cent of the issued ordinary share capital of the Company.
T May
Company Secretary
Notes to Editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) (LSE: SHP ; NASDAQ: SHPGY) is a
global specialty pharmaceutical company with a strategic focus on meeting the
needs of the specialist physician and currently focuses on developing and
marketing products in the areas of central nervous system (CNS),
gastrointestinal (GI), general products and human genetic therapies. Shire
has operations in the world's key pharmaceutical markets (US, Canada, UK,
France, Italy, Spain and Germany) as well as a specialist drug delivery unit
in the US.
For further information on Shire, please visit the Company's website:
http://www.shire.com.
SOURCE Shire Pharmaceuticals Group plc
 back to top
CONTACT:
For further information please contact:
Investor Relations: Clea Rosenfeld (Rest of the World),
+44-(0)1256-894-160 or Brian Piper (North America),
+1-484-595-8252
|
